Review of New Approach Methodologies for Application in Risk Assessment of Nanoparticles in the Food and Feed Sector: Status and Challenges
| Authors |
|
|---|---|
| Publication date | 09-2024 |
| Journal | EFSA Supporting Publications |
| Article number | 8826E |
| Volume | Issue number | 21 | 9 |
| Number of pages | 178 |
| Organisations |
|
| Abstract |
New Approach Methodologies (NAMs), broadly understood to include in silico, in chemico, in vitro and ex vivo
methods, show great potential in advancing risk assessment albeit their
regulatory implementation is lagging. The EFSA Guidance on risk
assessment of nanomaterials (EFSA Guidance on Nano-RA) suggests
nano-specific risk assessment is best achieved through Integrated
Approaches to Testing and Assessment (IATAs) with NAMs as the first
choice to generate new information. Integrating NAMs in risk assessment
promises several advantages such as a better human focus, more detailed
insights into molecular mechanisms and a higher efficacy. However,
applying NAMs to NMs also poses considerable challenges such as issues
related to dispersion stability, dosimetry, agglomeration, dissolution,
transformations or assay interferences. Significant efforts are being
undertaken by standardisation organisations and research projects to
establish various NAMs for NMs. Here a thorough review is provided
covering NAMs that will be potentially useful for risk assessment of NMs
in the food and feed sector. It follows the structure of the EFSA
Guidance on Nano-RA and expands it, where needed, to support
decision-making in selection of NAMs for NM risk assessment. The review
begins with an overview on nano-specific NAM-frameworks, followed by a
description of individual NAMs including those relevant to NM
physicochemical characterisation, exposure and hazard assessment
covering toxicodynamics and toxicokinetics. The focus is on NAMs
concerning NM degradation/dissolution, genotoxicity, cytotoxicity,
oxidative stress, (pro-)inflammation, and barrier integrity as those are
important endpoints for initial screening according to the EFSA
framework. As a result, in total 267 individual nano-relevant NAMs,
mostly “not validated” (with a few notable exceptions), were included in
this review. Validation notwithstanding, NAMs could already prove
relevant and reliable for risk assessment of NMs, especially in
integrated approaches.
|
| Document type | Article |
| Note | With supplementary files |
| Language | English |
| Published at | https://doi.org/10.2903/sp.efsa.2024.EN-8826 |
| Other links | https://nsc-community.eu/nsc-overview/nsc-structure/ongoing-projects/nams4nano/ |
| Downloads | |
| Supplementary materials | |
| Permalink to this page | |
